Pfizer CEO 'Cautiously Optimistic'
Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's ...
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...
After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely ...
Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at leveraging advanced analytics and knowledge graph AI to drive innovation in Pfizer’s drug discovery and development ...
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...
Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its ...
Pfizer’s chief executive said he was “disappointed” with Robert F Kennedy Jr’s refusal to disavow the debunked link between vaccines and autism, even as he expressed confidence that the Trump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback